Mylan and Lupin have gained the necessary recommendation to begin marketing their etanercept biosimilar in Europe.
Nepexto, an etanercept biosimilar, has gained a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use, recommending use of the product.
Nepexto has received a positive opinion for all indications of the reference product (Enbrel), including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis (including ankylosing spondylitis and nonradiographic axial spondyloarthritis), plaque psoriasis, and pediatric plaque psoriasis, according to Mylan NV and Lupin Limited, which have partnered in the development of the biosimilar.
“This milestone brings us 1 step closer to bringing an affordable biosimilar to etanercept to the European market through our partner Mylan,” said Vinita Gupta, chief executive officer of Lupin, in a statement. The companies began collaborating in 2018 to bring an etanercept biosimilar to the European market.
Enbrel, marketed by Amgen and Wyeth Pharmaceuticals, had sales of roughly $9.6 billion globally in 2019, according to IQVIA. In the United S, the comparable revenue figure was $5 billion.
The EMU committee opinion was based on a bioequivalence assessment that included preclinical and clinical studies. In addition, a phase 3 clinical study in patients with moderate-to-severe active rheumatoid arthritis confirmed equivalence of Nepexto to the reference product in terms of efficacy, safety, and immunogenicity, the statement said.
There are 2 approved etanercept biosimilars in the US: Samsung Bioepis’ Eticovo and Sandoz’ Erelzi. However, neither has launched. Erelzi received FDA approval in 2016 and has been delayed by litigation. Eticovo was approved in 2019, and no launch date has been announced.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.